Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.
The current treatment of neuroendocrine tumors include the use of somatostatin (SST) agonists. These compounds are able to control most of the symptoms caused by the hypersecretory activity of the tumor cells, and for this reason, they provide a significant improvement in the well-being of the patients. Although, several reports also showed a possible direct antiproliferative activity of SST agonists in different neuroendocrine tumors, the therapeutic potential of an in vivo antiproliferative activity mediated by SST receptors is still debated. In recent years, there has been great insights on understanding the molecular basis of the antitumoral activity of SST that appears to be exerted via both direct and indirect mechanisms. Direct mechanisms require the activation of SST receptors in tumor cells and the induction of cell cycle arrest or apoptosis, mainly through the regulation of phosphotyrosine phosphatase (PTP) and MAP kinase activities. The indirect mechanisms involve the inhibition of tumor angiogenesis and the inhibition of the secretion of factors which are required for tumor growth. Here, we will review the molecular mechanisms which are implicated in the antiproliferative activity of SST. Such an understanding is necessary for improving the antitumoral efficacy of SSTR agonists as well as for the development of novel therapeutic strategies.
Florio
Tullio
T
Laboratory of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, viale Benedetto XV, 2, 16132 Genova, Italy. tullio.florio@unige.it
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D015220:Calcium Channels / Q000378:metabolism; D049109:Cell Proliferation; D000242:Cyclic AMP / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020935:MAP Kinase Signaling System; D008954:Models, Biological; D009000:Monocytes / Q000378:metabolism; D009389:Neovascularization, Pathologic; D018358:Neuroendocrine Tumors / Q000378:metabolism*; D015221:Potassium Channels / Q000378:metabolism; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D015220:Calcium Channels; D015221:Potassium Channels; D017481:Receptors, Somatostatin; D000242:Cyclic AMP; D017027:Protein Tyrosine Phosphatases